This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. The mRNA jab, developed by Pfizer and BioNTech, launched to huge fanfare in December 2020 and promised the start of the end of the coronavirus pandemic.
As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.
In 2020, the pharmaceutical supply chain faced one of its biggest global challenges. To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date.
The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?
Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.
Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.
According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK.
It currently appears highly unlikely that the majority of conferences will simply return to typical face-to-face only formats as they were before 2020. This article summarises the most important lessons learnt during 2020 – 2021. Lessons learnt 2020-2021. yes, if vaccines are available; 15.8% yes; and 15.7%
She says she is “truly amazed” about what the industry has achieved in such a short time when it comes to innovations, vaccines and treatments. “When we come together like this, innovation can happen a lot faster.”. Connect with Dr Tunnah at [link] or [link].
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
Rewind to March of 2020, and pharma companies were facing a communication crisis. Other uses include providing a platform for key opinion leaders (KOLs), as well as internal communications to make sure that messages are unified across an organisation. The crisis that changed everything.
Data from Ofcom in 2020 found that just under one in five over-75s use a smartphone. As the vaccine roll-out continues, and GPs find more of a rhythm to their everyday appointments again, it’s time to reassess what is, and isn’t important when it comes to providing digital healthcare in the long-term. Be transparent.
Build a base in the community. According to the FDA’s 2020 Drug Trials Snapshot Report , only 8% of clinical trial participants are Black or African American, as compared to nearly 14% of the US population. The fact is, many minorities never learn about vital clinical trials in play, or that they’re eligible to participate.
The European Medicines Agency (EMA) issued its implementation guidance in March 2020. Journal of Pharmaceutical Sciences 109 (2020):1427–1438. Published March 2020. Published March 2020. December 2020. October 2020. Journal of Pharmaceutical Sciences (2021). doi:10.1016/j.xphs.2021.09.046. 2021.09.046.
Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. How to improve payer engagement with tailored value communication.
trillion by end of 2020. As the vaccines were developed and rolled out, the disparity in their take up among different sections of the community highlighted how excluded some minority communities felt from areas of healthcare. This already significant industry is growing – it is estimated to be worth $1.27
They showed how repetitive patterns of DNA are copied during replication, and found evidence they can stall the process entirely, increasing the risk of errors that can be an early driver of cancer, according to a paper published in the journal Nature Communications. The company signed a collaboration with Boehringer Ingelheim worth up to $1.07
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. 2020 Oct 16;9(1):219-228. Hemophilia News Today.
While the UK fully left the EU in January 2020, Britain was to take part in the Horizon Europe scheme as an associated country. Similarly to its predecessor , Horizon 2020, Horizon Europe is the EU’s research and innovation funding program, with a €95.5 billion ($103 billion) budget. Please check your email to download the Report.
Throughout the year 2020, pharma marketers were forced to explore new strategies in order to keep up with the many evolving trends. Trend #1: Media and Tech: Facilitating Communication. For example, people mistrust the efficiency and safety of the COVID-19 vaccine. Trend #3: Relationships Despite Digital Congestion.
Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world. The European Commission’s Pharmaceutical Strategy for Europe , adopted in November 2020, outlines a series of concrete actions to ensure accessibility, availability, and affordability of medicines.
Also, DCT-related home health and/or televisits are coordinated and followed on these platforms while allowing site teams to maintain ongoing communication with patients to provide visit reminders and other contact, which enhances retention every step of the way. are collected and housed together for study team monitoring and oversight.
He pointed out that the most recently developed MRAs were established between the EMA and the FDA and include inspections for veterinary products, vaccines, and plasma-derived products. He further suggested that appropriate resources should be available on-site to help host the inspection and use of different communication platforms.
In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. This is likely something we will be living with until we crack the code on how to vaccinate the unvaccinated, and even then we’re all likely to be getting boosters for a long-time. In this article, R.J. Innovation & Experimentation.
Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report. Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds.
Independent communications agency OVID Health has appointed Niall Dickson, professor David Salisbury and Athena Lamnisos as senior counsel, providing strategic advice and thought leadership across several projects involving healthcare and pharma clients. In addition to these appointments, Grace Holland has joined the team as account manager.
If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. So as the focus shifts from cost to value, we are now seeing cloud as a CEO agenda item.
For the pharma supply chain in particular, 2020 and 2021 were boom years in terms of investment. The Covid-19 pandemic created a new appetite for pharmaceutical innovation – dulled by recent economic troubles, but ravenous compared to pre-2020 averages. Figure 1: Worldwide venture capital investment in pharmaceutical firms since 2018.
A 2020 survey from DrugsDisclosed.com of 3,346 users of prescription and over the counter (OTC) medicines from the UK and the Nordics revealed that: more than three-quarters of patients do not trust advice from pharmaceutical companies about their medication; 81% feel the pharmaceutical industry influences prescription decisions; and.
The imminent rule changes will apply to crisis-relevant supplies of medical countermeasures, including both vaccines and therapeutics, where the threshold of a 'serious cross-border threat to health' is met. Some non-communicable diseases are, however, clearly covered and openly talked about for possible joint procurement prioritisation.
But when the pandemic struck in early 2020, we were found wanting. And we transformed so quickly because the key players communicated and collaborated. Surgical activity in England and Wales alone reduced by a third during 2020, a shortfall estimated to increase to 2.4 This will, inevitably, take longer in some areas.
In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not decades). He holds degree in Electronics and Communications Engineering. and consulting roles.
Marjo Loisa, the director of communications at THL, told the newspaper that “90% of tweets related to the coronavirus are highly inappropriate, and people are joining other discussions with disinformation as well.” Since its inception in March 2020, 11.72
Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Big pharma might have dominated COVID headlines with its vaccine drive, but behind the scenes an army of SMEs has allowed the UK to respond swiftly to the pandemic.
With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people around the globe were tuned in to every step of the fight against the pandemic, eagerly learning about everything from symptoms to vaccine development. Long-term partners. based site management organization.
Choosing between Fasenra and Nucala to manage severe asthma requires complex decision-making and communication with your healthcare provider, but having an understanding of how the drugs work can help you understand why they may prescribe one over the other. A systematic review published in 2020 did just that and included Fasenra and Nucala.
Reintroducing the liaison role of International Board members with individual Chapters and Affiliates has given us direct lines of communication to the mutual benefit of the International Board and the local groups. What else did I do as Chair this year, in addition to running the Board and its meetings plus sitting on numerous committees?
During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. October 2020. 16 October 2020. Burke, S.,
3 (2020):e2970. Nature Communications 12, no. Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5102 (19CP02) in RR NHL.” “Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” 16 June 2020. New Project: Evolutive Vaccines Facility for Sanofi.”
In fact, more than 95% of Americans live within just a few miles of a community pharmacy, which is one reason why pharmacies will be on the frontlines of administering the COVID-19 vaccine once it’s available.
During the peak of the Covid-19 pandemic this challenge reached new heights, as pharmaceutical firms around the world mobilised the full might of their resources to try and identify, develop, and trial a wide range of vaccines and therapeutics to alleviate the lethal threat posed by the virus. This was up from 11% in 2020.
The global pandemic created an unprecedented demand for vaccines, shut down many clinical trials, and resulted in a worldwide PPE shortage. In addition, we have seen clear public support and interest in the pharma industry during the pandemic, and it was necessary to communicate this openly to the world.
Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic. The storage and transportation of temperature-sensitive pharmaceutical products, such as vaccines and biologics, require strict temperature control throughout the supply chain to maintain their efficacy.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content